Thyroid

Thyroid is a monthly peer-reviewed journal founded in 1990 as the flagship publication of the American Thyroid Association, now published by SAGE Publications, covering thyroid cancer and all thyroid-related diseases, with a 2025 Journal Impact Factor of 6.6《Thyroid》（甲状腺）创刊于 1990 年，是美国甲状腺协会（ATA）的旗舰月刊，现由（SAGE Publications）出版，聚焦甲状腺癌与各类甲状腺疾病，2025 年影响因子为 6.6。

Scope

• The journal is a leading peer-reviewed resource for original articles, patient-focused reports and translational research on thyroid cancer and all thyroid-related diseases, delivering the latest findings from primary care to clinical application该刊是甲状腺癌与各类甲状腺疾病领域原创论文、关注患者的报告及转化研究的权威同行评议平台，报道从初级保健到临床应用的最新发现。
• It is the exclusive source for the authoritative and updated American Thyroid Association Guidelines for Managing Thyroid Disease, including the 2015 guidelines on nodules and differentiated thyroid cancer, the 2016 guidelines on hyperthyroidism and the 2025 guidelines on adult differentiated thyroid cancer该刊是美国甲状腺协会（ATA）甲状腺疾病管理指南的独家发布平台，先后发表 2015 年甲状腺结节与分化型甲状腺癌指南、2016 年甲状腺功能亢进症指南以及 2025 年成人分化型甲状腺癌管理指南。
• Clinical coverage includes thyrotoxicosis, thyroid hormone resistance and hypothyroidism, thyroid status testing, autoimmune thyroid illness and dysthyroid orbitopathy also known as Graves' ophthalmopathy临床覆盖范围包括甲状腺毒症、甲状腺激素抵抗与甲状腺功能减退、甲状腺功能检测、自身免疫性甲状腺疾病以及甲状腺相关眼病（又称格雷夫斯眼病）。
• Surgical and diagnostic themes span nodular thyroid disease, thyroid surgery, thyroid imaging, pediatric and neonatal thyroid disorders, genetics of thyroid disease and thyroid diseases in pregnancy外科与诊断主题涵盖结节性甲状腺疾病、甲状腺手术、甲状腺影像、儿科与新生儿甲状腺疾病、甲状腺疾病遗传学以及妊娠期甲状腺疾病。
• Basic science coverage addresses iodine deficiency and the goiter-hypothyroidism-neurological dysfunction spectrum, cell biology of the thyrocyte, nuclear and extranuclear actions of thyroid hormones, brain-pituitary-thyroid regulation and animal models of thyroid disease基础研究覆盖碘缺乏与地方性甲状腺肿-甲状腺功能减退-神经功能障碍谱系、甲状腺细胞的细胞生物学、甲状腺激素的核内与核外作用、下丘脑-垂体-甲状腺轴调控以及甲状腺疾病动物模型。
• The intended audience comprises endocrinologists, obstetricians, surgeons, primary care clinicians, oncologists, cell biologists and pathologists, reflecting the multidisciplinary nature of the field目标读者包括内分泌学家、产科医师、外科医师、初级保健临床医师、肿瘤学家、细胞生物学家与病理学家，体现该领域的多学科属性。

History

• The journal was founded in 1990 by Mary Ann Liebert, Inc. in collaboration with the American Thyroid Association, and the idea for a title devoted strictly to thyroid disease was pursued by ATA president John Wilber and secretary Len Wartofsky, with the sponsoring contract approved by the ATA Council and presented at the 10th International Thyroid Congress in The Hague in February 1991该刊于 1990 年由（Mary Ann Liebert）与美国甲状腺协会合作创办；创办一份专治甲状腺疾病的期刊的构想，由时任 ATA 主席（John Wilber）与秘书（Len Wartofsky）推动，赞助合同经 ATA 理事会批准，并于 1991 年 2 月在海牙举行的第 10 届国际甲状腺大会上提交会员审议。
• The inaugural issue of Volume 1 was dated 1990 and was a special memorial to the life and achievements of Sidney H. Ingbar, guest-edited by Leonard Wartofsky, and Jerome Hershman was selected as the first Editor-in-Chief, serving until 1999第 1 卷第 1 期出版于 1990 年，是纪念（Sidney H. Ingbar）生平与成就的特刊，由（Leonard Wartofsky）担任客座编辑；（Jerome Hershman）获选首任主编，任职至 1999 年。
• Mary Ann Liebert provided the initial financial support, and the journal was published quarterly from 1991 to 1994, moved to bimonthly from 1995 to 1997 and became a monthly title in 1998 as the flow of accepted articles increased（Mary Ann Liebert）为创刊提供了初期资金支持；该刊 1991 至 1994 年为季刊，1995 至 1997 年改为双月刊，并随录用稿件增加自 1998 年起改为月刊。
• The journal was accepted by MEDLINE in 1990 and by Current Contents in 1992, and the publisher digitized the full text of the early volumes in 2009 so that all issues remain accessible该刊 1990 年被 MEDLINE 收录，1992 年被 Current Contents 收录；出版方于 2009 年将早期卷期全文数字化，使全部过刊仍可查阅。
• Successive Editors-in-Chief have been Jerome Hershman (1990-1999), Terry Davies (2000-2007), Charles Emerson (2008-2012), Peter Kopp (2013-2019), Electron Kebebew (2019-2022) and Anna Sawka (since 2022), and stewardship transferred from Mary Ann Liebert to SAGE Publications with effect from 11 December 2024历任主编依次为（Jerome Hershman）（1990-1999 年）、（Terry Davies）（2000-2007 年）、（Charles Emerson）（2008-2012 年）、（Peter Kopp）（2013-2019 年）、（Electron Kebebew）（2019-2022 年）与（Anna Sawka）（2022 年至今）；该刊主办权自 2024 年 12 月 11 日起由（Mary Ann Liebert）移交（SAGE Publications）。^[1]
• The journal marked its 30th anniversary in 2020 and its 35th anniversary in 2025, received 785 manuscript submissions in 2025 with an overall acceptance rate of 19 percent, and its impact factor reached 6.7 in 2024 and 6.6 in 2025 with a five-year impact factor of 6.5该刊于 2020 年迎来创刊 30 周年、2025 年迎来 35 周年；2025 年共收到投稿 785 篇，总录用率为 19%；其影响因子 2024 年为 6.7、2025 年为 6.6，五年影响因子为 6.5。^[2]

Editors

• The Editor-in-Chief is Anna M. Sawka, MD, PhD, of the Division of Endocrinology at University Health Network and the University of Toronto in Canada, an endocrinist whose vision for the journal spans basic, translational and clinical thyroidology as well as health policy and epidemiology主编为加拿大多伦多大学附属医疗网络内分泌科的（Anna M. Sawka）医学博士、哲学博士；作为内分泌学家，其办刊愿景覆盖甲状腺学的基础、转化与临床研究以及卫生政策与流行病学。
• Four Editors-in-Chief Emeritus support the journal: Terry F. Davies of the Icahn School of Medicine at Mount Sinai, Charles H. Emerson of the University of Massachusetts, Electron Kebebew of Stanford University and Peter A. Kopp of the University of Lausanne四位荣休主编鼎力支持该刊：西奈山伊坎医学院的（Terry F. Davies）、马萨诸塞大学的（Charles H. Emerson）、斯坦福大学的（Electron Kebebew）与洛桑大学的（Peter A. Kopp）。
• Nine Associate Editors span North America, Europe, Asia and Australia, including Sheue-yann Cheng of the National Cancer Institute, Haixia Guan of Guangdong Provincial People's Hospital, Don McLeod of the Royal Brisbane and Women's Hospital and Douglas Ross of Massachusetts General Hospital九名副主编分布于北美、欧洲、亚洲与澳洲，包括美国国家癌症研究所的（Sheue-yann Cheng）、广东省人民医院的（Haixia Guan）、澳大利亚皇家布里斯班与妇女医院的（Don McLeod）以及马萨诸塞总医院的（Douglas Ross）。
• Avital Harari of the David Geffen School of Medicine at the University of California serves as Social Media Editor, and the editorial board is international and multidisciplinary across endocrinology, surgery, oncology, nuclear medicine and pathology加州大学戴维·格芬医学院的（Avital Harari）担任社交媒体编辑；编委会具有国际化与多学科特征，覆盖内分泌、外科、肿瘤、核医学与病理等方向。
• The Editor-in-Chief considers all submissions, conducts initial triage and assigns manuscripts to the appropriate specialty editor, supported by a strong team of Associate Editors and virtual editorial support staff主编审阅全部投稿并进行初筛分流，将稿件指派给合适的专业编辑，并由实力雄厚的副主编团队与虚拟编辑支持人员协助。
• According to the American Thyroid Association, the time to first decision is 40 days, from submission to publication is 138 days and from acceptance to publication is 20 days, with 33 percent of submissions rejected without external review据美国甲状腺协会公布的数据，该刊首次决定平均 40 天，投稿至发表平均 138 天，录用至发表 20 天，33% 的稿件未经外审即被拒稿。